SCHEMBL2900368

SCHEMBL2900368

CC(C)(C)[Si](OCc1nnc(C=O)s1)(c1ccccc1)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.34
POLB P06746 3/20 0.32
RAB9A P51151 1/20 0.32
LMNA P02545 1/20 0.32
HSD17B10 Q99714 1/20 0.32
SMYD2 Q9NRG4 2/20 0.31
CYP3A4 P08684 1/20 0.31
HTT P42858 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
KMT2A Q03164 1/20 0.30
TP53 P04637 1/20 0.30
TSHR P16473 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2899316 0.80 POLB (0.34) ALDH1A1POLBRAB9ALMNAHSD17B10
SCHEMBL17001546 0.78 ALDH1A1 (0.40) ALDH1A1SMYD2CYP3A4HTTSMN1; SMN2
SCHEMBL5777952 0.75 HTR2B (0.36) ALDH1A1RAB9ASMYD2CYP3A4HTT
SCHEMBL2894202 0.74 P2RY1 (0.39) ALDH1A1RAB9AHSD17B10SMN1; SMN2KMT2A
SCHEMBL4116949 0.74 SMYD2 (0.31) SMYD2CYP3A4HTTSMN1; SMN2
SCHEMBL304400 0.72 PPARG (0.39) ALDH1A1RAB9ALMNASMYD2CYP3A4
SCHEMBL21854492 0.72 SLC6A3 (0.38) CYP3A4HTTSMN1; SMN2KMT2A
SCHEMBL875044 0.72 BACE1 (0.39) ALDH1A1LMNASMYD2CYP3A4HTT
SCHEMBL21854465 0.71 CCNE1 (0.36)
SCHEMBL2532709 0.70 SMYD2 (0.36) SMYD2CYP3A4HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318746-B2 Nitrogen-containing five-membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-27 US disclosed
US-8318746-B2 Nitrogen-containing five-membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-27 US disclosed
US-20100130446-A1 NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAS COMPANY LIMITED (JP) 2010-05-27 US disclosed
US-20100130446-A1 NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAS COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-2149550-A1 NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-02-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130446-A1 NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND GCKR, GCK, SLC5A1 ALDH1A1 842/4885POLB 3839/4885RAB9A 3633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.